(Q54858822)

8 June 2018

title

Epitope mapping reveals the binding mechanism of a functional antibody cross-reactive to both human and murine programmed death 1. (English)

1 reference

8 June 2018

author name string

Dong Li

1

1 reference

8 June 2018

Jianqing Xu

2

1 reference

8 June 2018

Zhuozhi Wang

3

1 reference

8 June 2018

Zhen Gong

4

1 reference

8 June 2018

Jieying Liu

5

1 reference

8 June 2018

Yong Zheng

6

1 reference

8 June 2018

Jian Li

7

1 reference

8 June 2018

Jing Li

8

1 reference

8 June 2018

publication date

23 February 2017

1 reference

8 June 2018

published in

Monoclonal Antibodies

1 reference

8 June 2018

volume

9

1 reference

8 June 2018

issue

4

1 reference

8 June 2018

page(s)

628-637

1 reference

8 June 2018

Novel immunotherapy in the treatment of advanced non-small cell lung cancer

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419084

Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology

8 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419084

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues

8 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419084

Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis.

8 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419084

Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma

8 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419084

Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1.

8 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419084

The future of immune checkpoint therapy

8 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419084

Immunotherapeutic approaches to ovarian cancer treatment

8 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419084

PD-1 as a potential target in cancer therapy

8 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419084

The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies

8 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419084

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

8 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419084

Structure and Interactions of the Human Programmed Cell Death 1 Receptor

8 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419084

Tumor Immunotherapy Directed at PD-1

8 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419084

IL-22R, IL-10R2, and IL-22BP binding sites are topologically juxtaposed on adjacent and overlapping surfaces of IL-22.

8 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419084

The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors

8 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419084

PD-1 and its ligands in tolerance and immunity

8 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419084

PD-1 and PD-1 ligands: from discovery to clinical application

8 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419084

A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer

8 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419084

Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy

8 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419084

B7-H1 pathway and its role in the evasion of tumor immunity.

8 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419084

Multi-fragment site-directed mutagenic overlap extension polymerase chain reaction as a competitive alternative to the enzymatic assembly method.

8 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419084

Economic evaluation on infant hepatitis B vaccination combined with immunoglobulin in China, 2013

13 August 2018

1 reference

Crossref

https://api.crossref.org/works/10.1080%2F19420862.2017.1296612

10.1080/19420862.2017.1296612

21 January 2018

Identifiers

DOI

1 reference

8 June 2018

PMCID

5419084

1 reference

8 June 2018

PubMed ID

28300475

1 reference

8 June 2018